Harvey Kramer, MD
Cardiovascular Disease · Danbury, CTNPI 1518993302
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,531 of the $80,828 with a category attached, or 91.0%. 16 manufacturers reported payments, led by Boehringer Ingelheim at 27.0% of the total. Reporting peaked in 2019 at $30,960 and has fallen 61.1% since, to $12,031 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $612.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$22K
- Sanofi-aventis U.S. LLC$21K
- Esperion Therapeutics, Inc.$14K
- Lilly USA, LLC$13K
- Amgen$6K
- Regeneron Healthcare Solutions, Inc.$4K
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$73,53191%
- Travel & lodging$3,4884%
- Food & beverage$3,7565%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $21,795 |
| Sanofi-aventis U.S. LLC | 19 | $21,025 |
| Esperion Therapeutics, Inc. | 13 | $13,624 |
| Lilly USA, LLC | 13 | $13,129 |
| Amgen | 10 | $6,133 |
| Regeneron Healthcare Solutions, Inc. | 10 | $3,837 |
| Abbott | 3 | $320 |
| E.r. Squibb & Sons, L.L.C. | 6 | $238 |
| Novo Nordisk | 7 | $136 |
| Merck | 5 | $134 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $114 |
| AstraZeneca | 5 | $108 |
| Novartis | 5 | $83 |
| Bayer | 2 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Pfizer | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,828 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 799 | $1,071,172 |
| EntrestoSacubitril/Valsartan | 181 | $281,101 |
| JardianceEmpagliflozin | 171 | $218,816 |
| XareltoRivaroxaban | 100 | $138,881 |
| Repatha SureclickEvolocumab | 113 | $113,123 |
| FarxigaDapagliflozin Propanediol | 68 | $90,927 |
| Praluent PenAlirocumab | 73 | $46,822 |
| Repatha SyringeEvolocumab | 28 | $35,076 |
| Ezetimibe | 1,068 | $24,734 |
| Rosuvastatin Calcium | 1,512 | $21,752 |
| NexletolBempedoic Acid | 16 | $18,935 |
| Metoprolol Succinate | 1,261 | $15,940 |
| Ranolazine ErRanolazine | 95 | $15,509 |
| Atorvastatin Calcium | 1,453 | $14,420 |
| Colesevelam Hcl | 64 | $13,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $1,071,172799 claims |
| NovartisEntresto | $83 | $281,101181 claims |
| Boehringer IngelheimJardiance, Pradaxa | $21,795 | $225,792192 claims |
| AstraZenecaFarxiga, Brilinta | $108 | $98,46279 claims |
| Esperion Therapeutics, Inc.Nexletol | $13,624 | $18,93516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Danbury
- Jonathan AlexanderDanbury$12K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.